Expression of STEAP-1 and p40 in Prostatic Carcinoma and Its Mimickers

NCT ID: NCT05428319

Last Updated: 2022-09-08

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 70 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2022-12-31
• Study Completion Date: 2024-12-31

Brief Summary

Prostatic carcinoma is the second most common cancer in men with high incidence of morbidity and mortality. It is a common health problem. Most cases occur at the age of 50 years, reaching its peak at 60-70 years of age. Diagnosis of prostatic carcinoma is still a problematic issue as accurate diagnosis can be very challenging due to the presence of either a small focus of cancer or the presence of many benign mimickers of malignancy.

Six transmembrane epithelial antigen of the prostate 1 (STEAP-1) is primarily localized at the cell membrane, mostly at cell-cell junctions, but it may also be found dispersed in the cytoplasm. In prostate, the expression of STEAP-1 is higher in neoplastic tissues compared to its restricted expression in normal prostatic samples.

The antibody designated as p40 recognizes exclusively ΔNp63 and not TAp63. In prostate tissues, it has been shown that p40, the ΔNp63 isoform of p63, stains prostatic basal cells as reliable as p63 in most cases. Furthermore, aberrant staining of tumor cells was seen more rarely with p40 than with p63.

In this study, the investigators hope to solve some problematic issues in diagnosis of prostatic carcinoma and reach the better way to distinguish prostatic carcinoma from mimicking lesions by using both STEAP-1 and p 40. Also, the way to detect cancer at early stage of development and its progression which is extremely important as it allows establishing the most effective treatment and predicting patient's outcome.

Conditions

Prostatic Carcinoma

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: RETROSPECTIVE

Eligibility Criteria

Inclusion Criteria

• Trans-rectal ultrasound guided biopsy (TRUS) procedure, transurethral resection prostatectomy (TURP) and radical prostatectomy.
• Prostatic adenocarcinoma and prostatic lesions that mimic prostatic adenocarcinoma

Exclusion Criteria

• Patients with recurrence of the primary tumor.
• Patients with a history of preoperative chemotherapy and/or radiotherapy.
• Insufficient or tiny tissue biopsies

• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Sohag University

OTHER

Sponsor Role: lead

Responsible Party

Aliaa Bakr Ahmed

Assistant lecturer

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Aliaa Bakr

Role: PRINCIPAL_INVESTIGATOR

Faculty of medicine, Sohag University

Locations

Aliaa Bakr Ahmed

Sohag, , Egypt

Countries

Egypt

Central Contacts

Aliaa B Ahmed

Role: CONTACT

aliaa.bek0@gmail.com

01062157907

Other Identifiers

Soh-Med-22-06-14

Identifier Type: -

Identifier Source: org_study_id